Latest News

Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

30 March 2021

  • Since the anti-inflammatory effect of the nasally administered Foralumab is through the modulation of the immune system and not by directly targeting Covid-19, this...

Read more

Updated - Gabriele Cerrone, Chairman of Tiziana Life Sciences to give interview on Bloomberg Television US at 1:50 PM ET Tomorrow, 30 March 2021

29 March 2021

UPDATE

Read more

Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give interview on Bloomberg Television US at 1:20 PM ET Today

29 March 2021

NEW YORK and LONDON - 29 March 2021 - Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that the Chairman and Founder, Gabriele Cerrone, will give an...

Read more

Tiziana Life Sciences Interview to Air on Bloomberg Television US on the RedChip Money Report

26 February 2021

NEW YORK and LONDON - 26 February 2021 — Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that an interview with it’s CEO, Dr Kunwar Shailubhai,...

Read more

PDMR DEALING

05 February 2021

NEW YORK and LONDON – February 5, 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the...

Read more

APPOINTMENT OF DIRECTOR

05 February 2021

NEW YORK and LONDON – February 5, 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the...

Read more

Page 2 of 26 Previous Next